Cartesian Therapeutics Soars 15.44% on Positive Phase 2b Trial Data

On April 9, 2025, Cartesian Therapeutics' stock surged by 15.44% in pre-market trading, reflecting significant investor interest and optimism surrounding the company's recent developments.

Cartesian Therapeutics recently announced 12-month efficacy and safety data from the Phase 2b trial of Descartes-08 in participants with generalized myasthenia gravis (MG). The data showed that participants who received a single six-week course of Descartes-08 continued to experience sustained symptom improvement at the 12-month assessment. Notably, participants without prior exposure to biologic therapies exhibited the deepest and most compelling sustained responses, with an average 7.1-point reduction in MG-ADL and 57% of patients in this subgroup maintaining minimum symptom expression at Month 12.

The safety profile of Descartes-08 was consistent with previously reported data, supporting outpatient administration without the need for preconditioning chemotherapy. The Phase 3 AURORA trial is on track to dose the first patient in the second quarter of 2025, further advancing the development of this promising therapy.